Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

BACKGROUND: We previously reported that in patients with HER2‐positive (HER2+) locally advanced breast cancer treated with neoadjuvant trastuzumab‐containing regimens, high HER2 to centromere enumerator probe 17 ratio on fluorescence in situ hybridization (HER2 FISH ratio) was an independent predict...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Kogawa, Takahiro, Fujii, Takeo, Wu, Jimin, Harano, Kenichi, Fouad, Tamer M., Liu, Diane D., Shen, Yu, Masuda, Hiroko, Krishnamurthy, Savitri, Chavez‐MacGregor, Mariana, Lim, Bora, Murthy, Rashmi K., Valero, Vicente, Tripathy, Debu, Ueno, Naoto T.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288623/
https://ncbi.nlm.nih.gov/pubmed/32003919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0611
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares